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Abstract: Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new 
drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 
2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of 
treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, 
resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis 
(CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug dis-
covery and development.  
Keywords: Leishmaniasis, drug discovery, drug development. 
LEISHMANIASIS 
  Leishmaniasis is a disease complex caused by protozoan 
parasites of the genus Leishmania. Parasites are transmitted 
by female sandflies via anthroponotic or zoonotic cycles [1]. 
Leishmania parasites have a dimorphic life-cycle; promas-
tigotes develop in the gut of female sandflies to infectious 
forms that are transmitted to mammalian hosts [2,3]. Inside 
the host parasites survive and multiply as amastigotes within 
parasitophorous vacuoles (PVs) of macrophages [4,5]. Main 
clinical manifestations include visceral leishmaniasis (VL) 
and cutaneous leishmaniasis (CL) and rarer manifestations 
such as mucosal leishmaniasis and post-kala-azar dermal 
leishmaniasis (PKDL). An estimated 350 million people are 
at risk of infection and disease worldwide. The annual inci-
dence is estimated at 1.5 - 2 million with 70 000 deaths each 
year [1]. However due to underreporting and misdiagnosis 
actual case loads are expected to be higher. Leishmaniasis is 
included in the neglected tropical diseases (NTDs) [6] and a 
strong link to poverty is recognized [7]. Epidemiology, 
pathogenesis, diagnosis and disease control have recently 
been reviewed [1,8].  
DRUGS AVAILABLE AND IN CLINICAL TRIALS 
  The following paragraphs provide an overview of cur-
rently used and clinically investigated anti-leishmanial 
drugs. Consideration is given to clinical data, reported tox-
icities and pharmacokinetics (PKs), chemistry, their mode of 
action (MOA) and cellular targets.  
Pentavalent Antimonials 
  Pentavalent antimonials (meglumine antimonate (MA) 
and sodium stibogluconate (SSG)) have been used in the   
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treatment of VL and CL for more than 60 years. Response 
rates are still over 95% in previously untreated VL patients 
in many parts of the world, but acquired resistance to pen-
tavalent antimony (Sb
v) has developed in the high-
prevalence, high-transmission epidemic region of Bihar, In-
dia [9]. Failure rates of 65% have been reported and the use 
of antimony abandoned in this region [10]. Other issues re-
lated to treatment include confirmation of drug efficacy, side 
effects of low-cost generic drugs and lot-to-lot variation 
[11]. Cardiotoxicity has been reported as drug-induced effect 
[12,13]. Serious cardiotoxicity is seen in 9-10% of treated 
patients. Higher rates have been reported due to improper 
formulation of drug and use of lots with high osmolarity 
[13]. Pharmacokinetics of pentavalent antimonials has been 
described by a two compartment, three term pharmacokinetic 
model. An initial absorbtion phase was followed by a rapid 
elimination phase (mean half-life 2.02h) and a slow elimina-
tion phase (mean half-life 76 hours) in patients treated with 
MA or SSG [14]. In infected dogs treated with multiple 
doses of MA an absorption phase was followed by a rapid 
disposition phase (half-life  1.41 hours) and a slower termi-
nal phase (half-life  8.76 hours) [15].  
  The chemical structure and composition of meglumine 
antimonate and sodium stibogluconate have recently been re-
evaluated by electrospray ionization mass spectrometry 
(ESI-MS) and osmolarity measurements [16]. The authors 
reported that MA and SSG consist as mixtures of 2:2, 2:3 
and 2:1 Sb
v-ligand complexes in concentrated aqueous solu-
tions. Increasing depolymerisation occurs with increasing 
dilution and conversion of the highly aggregated state into 
dissociated complexes and antimonate is expected in human 
serum after drug administration. 1:1 Sb
v-ligand complexes, 
together with antimonate, are expected to be the final Sb
v 
form of these drugs and pharmacologically relevant [16].  
  Pentavalent antimonials are now generally accepted as 
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biological activity. The site of reduction (macrophage, amas-
tigote or both) and the mechanism (enzymatic or non-
enzymatic) remain unclear. Early studies have implicated 
inhibition of energy metabolism and macromolecular biosyn-
thesis via inhibition of glycolysis and fatty acid beta-
oxidation in the mechanism of action of sodium stibogluco-
nate [17,18]. Specific targets in these pathways have not 
been identified. Trivalent antimony has recently been shown 
to directly interfere with thiol metabolism in drug-sensitive 
L. donovani with several effects on glutathione and trypan-
othione metabolism [19].  
Amphotericin B 
  Amphotericin B is a polyene antibiotic, which was origi-
nally extracted from Streptomyces nodosus. Crystalline am-
photericin B is insoluble in water and different formulations 
are available. Amphotericin B deoxycholate (Fungizone®), a 
micellar formulation, is highly effective. It is used as first 
line treatment in areas with high rates of unresponsiveness to 
antimonials and second line treatment elsewhere [11]. Lipid 
based formulations of amphotericin B are available and 
liposomal amphotericin B (AmBisome®) has been approved 
for treatment of VL by the U.S. Food and Drug Administra-
tion (FDA) [20]. Shorter treatment courses and single dose 
regimes of liposomal amphotericin B have been investigated 
in the state of Bihar, India [21-23]. The most recent study 
tested the efficacy of liposomal amphotericin B at a single 
dose of 10 mg/kg in comparison to 15 alternate-day infu-
sions of amphotericin B deoxycholate at a dose of 1mg/kg. 
Single dose liposomal amphotericin B was not inferior to 
and less expensive than amphotericin B deoxycholate, but a 
non-significantly higher relapse rate was noted in the 
liposomal treatment group [24]. Other commercially avail-
able lipid formulations, amphotericin B lipid complex 
(ABLC) and amphotericin B colloidal dispersion (ABCD) 
have also been tested for treatment of VL [25]. A commer-
cially standardized product of amphotericin B deoxycholate 
premixed with lipid emulsion containing egg lecithin and 
soyabean oil (ABLE) is licensed in India for the use of VL. 
However overall cure rates in phase II clinical trials in India 
using this formulation as monotherapy were lower than the 
desired cure rate of approximately 95% [26,27].  
  Need for hospitalization, constant monitoring of patients, 
prolonged duration of treatment and infusion-related adverse 
events (fever, chills, trombophlebitis) are drawbacks of am-
photericin B deoxycholate. Toxicities such as hypokalaemia, 
nephrotoxicity and myocarditis can occur [12]. Liposomal 
amphotericin B is much safer than amphotericin B deoxy-
cholate and also highly efficacious [11,12]. However high 
cost limits widespread use in many VL-endemic regions. 
Recently new preferential pricing was agreed for certain 
countries with a cost of $20 per 50 mg vial of AmBisome® 
[28]. In liposomal amphotericin B drug is formulated with 
cholesterol and other phospholipids within a small unilamel-
lar liposome. Temperatures of >25ºC and <0ºC can alter 
liposome characteristics and may impact on efficacy and 
toxicity of liposomal amphotericin B [29]. ABLE is stable at 
higher temperatures for a certain time. 
  Characteristics that increase efficacy and minimize toxic-
ity of liposomal amphotericin B are effective tissue penetra-
tion with sustained levels and stability in blood, macro-
phages and tissues [29]. Tissue penetration is highest in liver 
and spleen. Preclinical pharmacokinetics of AmBisome® has 
been studied in mice, rats, rabbits and dogs. Its mean elimi-
nation half-life ranges from 5-24 hours depending on dose 
and species [30]. In humans the terminal elimination half-life 
after repeated administration of liposomal amphotericin B 
has been reported with around 7 hours [31]. Longer half-lifes 
have been reported with increased sampling times, but re-
ported data in Leishmaniasis patients is limited. A study on 
L. infantum infected mice treated with multiple doses of 
AmBisome® also found high levels of the drug in liver and 
spleen [32].  
  Selectivity of amphotericin B against Leishmania is due 
to higher affinity of amphotericin B for 24-substituted ster-
ols, the predominant sterol in Leishmania membranes, over 
cholesterol, the predominant sterol in mammalian cells. In-
teraction with membranes leads to formation of transmem-
brane amphotericin B channels, aqueous pores, and leakage 
of cations [33,34]. Selectivity and toxicity is also linked to 
the aggregation state of amphotericin B [34].  
Miltefosine 
  Miltefosine is an alkylphosphocholine, originally devel-
oped as anti-cancer drug. It was the first oral anti-leishmanial 
drug that reached the market and is registered for treatment 
of VL in India and Germany and for CL in Colombia. It is 
used as potential tool in the elimination programme in India, 
Bangladesh and Nepal and as second line treatment for CL in 
Colombia and Bolivia [11].  
  General safety findings indicate the gastrointestinal tract 
as main target organ of side-effects [35]. Gastrointestinal 
symptoms were also recognized as the most common ad-
verse effect in clinical trials [36]. Transient moderate eleva-
tion of hepatic enzymes was also observed. In a recent phase 
4 study and in previous trials adverse events occurred more 
frequently in the first week of treatment and decreased with 
time [36]. The major limitation of miltefosine is its contrain-
dication in pregnancy and mandatory contraception for 
women in child-bearing age for the duration of therapy and 
2-3 months beyond. This restriction is based on a teratogenic 
effect seen in one species (rat) in preclinical studies [35] and 
the pharmacokinetic profile of miltefosine.  
  A recent study described the pharmacokinetics of milte-
fosine by a two-compartment disposition model with a first 
elimination half life of 7.05 days and a terminal half-life of 
30.9 days in CL patients after treatment with 50 mg miltefos-
ine three times daily for a total of 28 days [37]. A long ter-
minal half-life of 150 – 200 hours has previously been re-
ported and concerns were raised that subtherapeutic levels of 
miltefosine in the body after completion of treatment might 
contribute to the emergence of resistance [38]. In the labora-
tory Leishmania promastigotes resistant to miltefosine con-
centrations of up to 40M were easily generated and resis-
tance was conferred to the intracellular amastigote stage 
[39,40].  
  Uptake of miltefosine into L. donovani is mediated by a 
plasma membrane P-type ATPase aminophospholipid trans-
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nia include perturbation of ether-lipid metabolism, glycosyl-
phosphatidylinositol (GPI) anchor biosynthesis and signal 
transduction [44] as well as inhibition of the glycosomal 
located alkyl-specific acyl-Co-A acyltransferase, an enzyme 
involved in lipid –remodeling [45]. Recently mitochondria 
and specifically the cytochrome c oxidase have been impli-
cated as target of miltefosine in L. donovani promastigotes 
[46]. Effects on lipid metabolism, specifically phospholipid 
content, fatty acid and sterol content, have also been de-
scribed in L. donovani promastigotes [47].  
Paromomycin 
  Paromomycin, an aminoglycoside antibiotic, is the latest 
anti-leishmanial drug registered for VL in India. In a ran-
domized, controlled, phase 3 study in India paromomycin 
was shown to be noninferior to amphotericin B with a final 
cure rate of 94.6% versus 98.8 % [48]. A recent study com-
pared 11mg/kg/day of paromomycin for 14 days to 
11mg/kg/day of paromomycin for 21 days in Indian VL. The 
definite cure rate in the short-course treatment group of 14 
days was significantly lower than the rate in the 21 day 
treatment group (82% versus 92% based on intention-to-treat 
analysis) [49].  
  Paromomycin has also been formulated for topical treat-
ment of CL [11,50]. It is used as topical treatment for CL in 
Israel in a methylbenzethonium chloride ointment (Leshcu-
tan) [50]. Recently a phase 2, placebo controlled study, car-
ried out in Tunisia and France, reported efficacy (cure rate 
94%) and safety of the third generation aminoglycoside 
ointment WR279,396, a hydrophilic formulation of 15% 
paromomycin plus 0.5% gentamicin [51]. Local treatment of 
CL in the form of topical formulations offer the advantage of 
ease of administration, fewer side effects and cost-
effectiveness in comparison to systemic treatment [52].  
  Injection-site pain was the most frequently reported ad-
verse event in the phase 3 trial for VL in India [48]. Ototox-
icity and nephrotoxicity are known drug class effects, but 
frequency of these reactions has been reported as low at 
therapeutic dosages for VL [50]. Ototoxicity in a small per-
centage of patients in the recent phase 3 trial was reported as 
transient and reversible and the drug had a reasonable safety 
profile [48]. Monitoring of hepatic enzyme levels was rec-
ommended in the recent short-course trial [49].  
  Pharmacokinetic data has been reported from VL patients 
during the phase 3 trial. Paromomycin was absorbed quickly 
after intramuscular injection. Peak plasma levels were 
reached within 1 hour. Plasma levels 1 hour after injection 
ranged from 18.3 μg/ml to 20.5 μg/ml and trough plasma 
levels at 24 hours after injection from 1.31 μg/ml to 4.53 
μg/ml. Plasma levels on days 1, 8, 15, 21 and 22 were simi-
lar [48]. Population estimates for absorbtion and elimination 
half-lives have been reported as 0.33 hours and 2.62 hours 
[50]. Pharmacokinetic data following a single intramuscular 
dose of paromomycin in healthy adult volunteers has also 
been reported [53].  
  Previous studies on paromomycin in Leishmania spp. 
have implicated mitochondrial membrane de-polarisation, 
ribosomes and respiratory dysfunction in the mode of action 
of this molecule [54-56]. Decreased drug uptake was shown 
in a paromomycin resistant L. donovani line [57]. Some of 
these findings have been confirmed in a recent study on L. 
donovani promastigotes [58].  
Pentamidine 
  Pentamidine is an aromatic diamidine, still in use as first 
line drug for certain forms of CL. In VL it is used as second-
line treatment only due to toxicity and efficacy issues [11]. 
The major safety concern with pentamidine is induction of 
insulin-dependent diabetes mellitus and in India its use for 
VL has been abandoned [12].  
  Early work has implicated the mitochondrion in the mode 
of action of pentamidine. Morphological changes with swel-
ling of mitochondria and fragmentation of kinetoplastid 
DNA were reported in electron microscopy studies on 
Leishmania spp [59,60]. An uncoupling effect on mitochon-
dria in situ with collapse of mitochondrial membrane poten-
tial was shown in L. donovani promastigotes [61]. Alkalisa-
tion of acidocalcisomes of L. donovani promastigotes has 
also been reported [62]. In a recent study mitochondria have 
been suggested as site of pentamidine accumulation in L. 
donovani and drug resistance associated with mitochondria 
alterations [63]. Pentamidine enters promastigotes and amas-
tigotes of Leishmania via a carrier mediated process which 
recognizes diamidines with high affinity [64]. 
Sitamaquine 
  Sitamaquine (WR6026) is an 8-aminoquinoline currently 
in clinical development by Glaxo Smith Kline for oral treat-
ment of VL [65]. Discovery of sitamaquine as anti-
leishmanial agent was based on extensive efforts in synthetic 
chemistry at the Walter Reed Army Institute for Research 
(WRAIR) [66]. Recently results were reported from phase II 
dose ranging studies in India and Kenya. The overall cure 
rate at day 180 in the intention-to-treat-population was 83% 
in Kenyan patients [67] and 87% in Indian patients [68]. 
Abdominal pain and headache were reported in the Kenyan 
study and vomiting, dyspepsia and cyanosis by the Indian 
investigators. Methemoglobinemia is associated with 8-
aminoquinolines, but was only reported in Indian patients 
[68].  
  Studies using rat and hamster liver microsomes have 
identified two major metabolites of sitamaquine, the desethyl 
and 4-CH2OH derivatives, with evidence of cytochrome P-
450 mediation [65,69]. Side chain oxidation and 5-
hydroxylation have been identified as important steps in the 
metabolic pathway of 8-aminoquinolines [65,70]. Pre-
systemic eliminiation of sitamaquine in the liver with low 
systemic availability was observed in Beagle dogs [71]. The 
elimination half-life of sitamaquine in humans is reported as 
26.1 hours. The major urinary metabolite in humans is the 4-
CH2OH derivative with a reported elimination half-life of 
29.1 hours. A minor metabolite in humans is the desethyl 
species [65]. Metabolites may be linked to efficacy and tox-
icity of this compound. 
  Sitamaquine induced morphological changes in intracel-
lular L. tropica amastigotes and host macrophages [59]. Col-
lapse of mitochondrial membrane potential in L. donovani 
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tion of acidocalcisomes [62]. Recently anti-leishmanial ac-
tivity has been demonstrated as unrelated to sitamaquine 
accumulation in this organelle [72]. The interaction of si-
tamaquine with membrane lipids of L. donovani promas-
tigotes has been assessed and described as a two-step process 
[73].  
  Chemotherapy and its role in treatment and control of 
leishmaniasis has recently been reviewed [11]. Treatment 
regimes of first and second line drugs against VL and CL 
and route of administration have been described [11,74].  
RECENT DEVELOPMENTS AND SELECTED DRUG 
CLASSES – FROM DISCOVERY TO PRECLINICAL 
STAGES 
  The following paragraphs describe some new develop-
ments at the discovery and development stage. These include 
new compounds and new formulations of compounds and 
drugs for which in vivo efficacy has been demonstrated in 
relevant animal studies.  
2-Substituted Quinolines 
  2-substituted quinoline alkaloids were originally isolated 
from a Bolivian medicinal plant (Galipea longiflora Kr, Ru-
taceae) and shown to have an effect in the treatment of ex-
perimental New World CL [75]. Activity of 2-substituted 
quinoline alkaloids was subsequently reported in the L. 
donovani – BALB/c mouse model with 2-n-propylquinoline 
showing significant activity after oral administration and 
chimanine D after subcutaneous administration [76]. Recent 
structure activity relationship (SAR) studies on a series of 2-
substituted quinolines concluded that the most active quino-
lines against intra-macrophage L. infanutm and L. ama-
zonensis amastigotes in vitro had a three carbon alkenyl side 
chain with reactive electrophilic functions such as carbonyl, 
hydroxyl or halogen [77]. Significant efficacy of selected 
compounds was demonstrated in L. amazonensis and L. 
donovani infected BALB/c mice after oral administration. 
One compound emerged as the single compound with satis-
factory activity across the in vivo models employed, contain-
ing a propenyl chain functionalized by an -OH group [78]. 
Biotransformation of this and other 2-substituted quinolines 
and their in vitro behavior in the blood compartment was 
studied  showing discrepancies of affinity to erythrocytes 
amongst this series [79,80].  
8-Aminoquinolines 
  8-aminoquinolines were originally developed as anti-
malarials, but have also shown promise in the treatment of 
leishmaniasis as seen with sitamaquine (WR6026, lepidine). 
Another 8-aminoquinoline, NPC1161, has shown activity 
against L. donovani in vivo in a similar order of magnitude to 
sitamaquine when tested as (-) enantiomer. Clear stereoselec-
tive differences in drug activity and toxicity were shown for 
this compound when tested as racemat, (-) or (+) enantiomer 
in the same study [81]. Synthesis and in vitro activities of 
other 8-aminoquinolines against L. donovani promastigotes 
have been reported [82,83]. These include derivatives with a 
5-(3-trifluoromethylphenoxy) substitution on the quinoline 
ring and methyl-substituted, ethyl-substituted or unsubsti-
tuted C4 positions [82]. Notably the 5-(3-trifluoromethyl-
phenoxy) substitution is also part of tafenoquine, another 8-
aminoquinoline with anti-parasitic activity [66].  
Buparvaquone and Derivatives 
  Buparvaquone is a hydroxynaphtoquinone, which is cur-
rently marketed as Butalex® for the treatment of theileriosis 
in cattle. It was demonstrated as being highly active in vitro 
against intracellular L. donovani amastigotes in macro-
phages, but less active in vivo in the BALB/c mouse [84]. Its 
potent  in vitro activity was recently confirmed against a 
range of Leishmania spp. with EC50 values for the intracellu-
lar amastigote stage in the low micromolar to nanomolar 
range [85]. The same study investigated water soluble phos-
phate prodrugs of buparvaquone and reported potent in vitro 
activity against CL and VL causing Leishmania species [85]. 
Buparvaquone oxime derivatives were also investigated, but 
displayed lower in vitro activity against L. donovani than the 
parent compound [86]. The prodrug approach is an effective 
way of improving oral bioavailability of poorly soluble drugs 
by chemical derivatization to more water soluble com-
pounds. It is also used to improve topical drug delivery. 
Formulations for topical delivery of buparvaquone and a 
prodrug (3-phosphono-oxymethyl-buparvaquone) have been 
developed and characterized in in vitro human and mouse 
skin models [87]. Efficacy of topical formulations and phos-
phate prodrugs of buparvaquone in in vivo models of VL and 
CL has been reported [88].  
New Amphotericin B Formulations 
  Recently a number of new amphotericin B formulations 
with high anti-leishmanial activity in vivo have emerged. 
The main focus of the re-formulation of this highly active 
molecule is to increase solubility and thermal stability and 
decrease systemic toxicity of amphotericin B. A reduced cost 
of new amphotericin B formulations is also desired. Solid 
nanoparticles of amphotericin B deoxycholate have shown 
activity after intraperitoneal injection into L. donovani in-
fected hamsters with 99% suppression of parasite replication 
in the spleen at a dose of 5mg/kg/day given for 5 days [89]. 
A novel lipid based amphotericin B formulation has recently 
been reported as active after oral administration in L. dono-
vani infected mice. Parasitemia in the liver was inhibited by 
99.5% and 99.8% at doses of 10 and 20 mg/kg twice daily 
for 5 days [90]. N-(2-hydroxypropyl)-methacrylamide-
GFLG-amphotericin B copolymer conjugates inhibited para-
sitemia by up to 94% in the liver of L. donovani infected 
BALB/c mice after intravenous administration of 1mg/kg 
amphotericin B equivalent on 3 alternate days and by up to 
99.6% at a dose of 3mg/kg amphotericin B equivalent [91]. 
This approach was extended to investigate poly(HPMA)-
GFLG-amphotericin B-alendronic acid conjugates as poten-
tial combination therapeutics in models of VL [92]. 
RECENT DEVELOPMENTS – CLINICAL AND USE 
OF ANTI-LEISHMANIAL DRUGS 
  The following paragraph describes new developments in 
the use of anti-leishmanial drugs available to patients. These 
include new treatment regimes in the form of combination 
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Combination Chemotherapy 
  Advances in anti-leishmanial chemotherapy including the 
development of new drugs have made combination chemo-
therapy a real possibility. Multi-drug therapy is already stan-
dard practice in the treatment of other infectious diseases 
such as tuberculosis, leprosy and malaria [93-96]. Drug 
combinations aim to delay or prevent the emergence of resis-
tance, shorten the course of treatment and lower required 
doses. Other potential advances include convenience, better 
compliance and lower costs [97]. A combination regime of 
sodium stibogluconate and paromomycin is currently em-
ployed in Sudan by Médecins sans frontiers (MSF) [98]. 
Single dose liposomal amphotericin B forms part of a new 
treatment approach for VL. A single dose of liposomal am-
photericin B was followed by a short-course treatment of 
miltefosine for 7 - 14 days in a recent study in India. Results 
were satisfactorily with cure rates >95% in the different 
treatment groups [97]. Further trials that investigate single 
dose liposomal amphotericin B followed by short treatment 
courses of miltefosine or paromomycin and the combination 
of miltefosine and paromomycin are completed, as is a trial 
investigating the combination of sodium stibogluconate and 
paromomycin (http://clinicaltrials.gov, accessed March 28
th 
2010).  
DRUG TARGETS IN LEISHMANIA AND CHEMICAL 
STRUCTURES 
  The following paragraphs describe potential drug targets 
in Leishmania with classes of chemical inhibitors where ap-
plicable and chemical structures for which a target has been 
demonstrated or a hypothesized target was starting point of 
the studies.  
Drug Targets 
  Protein kinases are key regulatory proteins and represent 
a drug target in Leishmania and other trypanosomatids. Mi-
togen-activated protein kinases (MAP kinases), LmxMPK1 
(Leishmania mexicana mitogen-activated protein kinase 1) 
and LmxMPK2 have been found essential for survival of 
amastigotes in infected hosts or the establishment of infec-
tions in mice [99]. Cyclin-dependent kinases have been 
chemically validated as potential drug targets by systematic 
analysis of chemical inhibitors. Thus L. mexicana CRK3 was 
screened against a chemical library of potential inhibitors 
and potent CRK3 inhibitors screened against intracellular L. 
donovani amastigotes in vitro. The most potent inhibitors 
were found to belong to the indirubin class of chemicals, 
others were 2, 6, 9-trisubstituted purines, paullones and de-
rivatives of the non-specific kinase inhibitor staurosporine 
[100]. Recently 6-bromo substituted indirubins were re-
ported as highly active in vitro against L. donovani and their 
action linked to CRK3 and GSK-3, a serine/threonine kinase 
[101]. Essentiality of protein kinases for proliferation and/or 
viability of the parasite and significant sequence differences 
from mammalian homologues are important points. The role 
of protein kinases as drug targets has been reviewed [102]. 
Currently the kinome of Leishmania is investigated in anti-
leishmanial drug discovery [103].  
  Proteases (peptidases) are also explored and character-
ized as potential drug target in Leishmania [104,105]. 
Chemical Structures 
  Pentamidine analogues and aromatic diamidines are still 
of interest in anti-leishmanial integrating drug screens. Struc-
ture activity relationships (SAR) of synthetic compounds 
have recently been reported [106,107]. Binding of diamidi-
nes to DNA has been described and characterized [108].  
  Azasteroles are nitrogen containing sterol compounds. 
Azasterols with a nitrogen in the side chain of sterols at the 
23-, 24-, or 25-position can inhibit the enzyme delta24-sterol 
methyltransferase (24-SMT) in fungi and plants and inhibit 
sterol biosynthesis [109]. A series of azasterols with and 
without protection at the C-3 of the sterol nucleus has been 
assessed, but multiple modes of action were found against 
Leishmania spp. In vitro acitivity of C-3 protected azasterols 
was reported against intracellular L. donovani amastigotes 
[109]. In vitro activity was also reported for transition state 
analogues of 24-SMT [110]. A recent SAR study by the 
same group on new series of azasterols provided further in-
sights into the pharmacophore of these compounds against L. 
donovani [111]. Their mode of action remains unclear.  
  Quinuclidine derivatives have shown in vitro activity 
against  L. donovani axenic amastigotes. They act as 
leishmanial squalene synthetase inhibitors disrupting en-
dogenous sterol biosynthesis [112].  
APPROACHES AND STRATEGIES IN ANTI-
LEISHMANIAL DRUG DISCOVERY AND DEVEL-
OPMENT 
  Different approaches are used in drug discovery with 
molecular-target based approaches and exploratory drug 
screening at both ends of the spectrum. Molecular ap-
proaches, whole cell based approaches and a compromise 
approach between the two have their own values in anti-
parasitic drug discovery [113-115]. Criteria for target as-
sessment and different target validation methods have re-
cently been described [113]. An open access database for 
tropical diseases has been established to merge data from 
genome sequencing and functional genomics projects, pro-
tein structural data and provide information on target essen-
tiality and druggability [115,116].  
  The development process is guided by target product 
profiles (TPP), a list of key attributes for potential new drugs 
[113,117]. For leishmaniasis these attributes entail activity 
against VL and CL, short treatment courses, injectable agent 
with reduced treatment time, the desire for an oral drug, an 
improved safety profile, costs less than current treatment, 
stability under tropical conditions, the desire for a topical 
application for CL and the potential to combine with exisit-
ing agents [117]. Definitions for “hit” and “lead” along with 
hit-to-lead identification criteria and lead optimization and 
candidate selection criteria have been summarized. These 
can be used complementary to the TPP in decision making 
on further progression of compounds in the development 
process [118].  
  A number of new public-private partnerships, non-profit 
organizations and consortia have been established in recent 
years to increase support of drug discovery and development 
for neglected and parasitic or tropical diseases. These include 36    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Karin Seifert 
the Drugs for Neglected Diseases Initiative (DNDi) and The 
Consortium for Parasitic Drug Development (CPDD). Phil-
anthropic organizations (including the Bill and Melinda 
Gates Foundation) and governments are also lending in-
creased (financial) support [114-119]. Long standing pro-
grammes such as the TDR Screening Network are continued 
and have evolved to address the need of different stages and 
aspects in the drug discovery and development process. 
These include target selection, medicinal chemistry and drug 
metabolism and pharmacokinetics (DMPK) [117,118]. The 
integration of these aspects and new technologies, either 
within an initiative or as networks of partners with comple-
mentary expertise is important to sustain and feed the devel-
opment pipeline.  
CONCLUSION  
  In recent years advances have been made in the treatment 
of leishmaniasis. New drugs and treatment regimes are avail-
able or on the way to availability. The approach to drug 
discovery and development has also changed and advanced 
to include and integrate aspects as outlined above. The need 
to search for better, safer and simpler treatments continues.   
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